EYEFILL® C. -US Viscoelastic Clinical Investigation

NCT ID: NCT02024711

Last Updated: 2020-09-04

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

262 participants

Study Classification

INTERVENTIONAL

Study Start Date

2013-12-31

Study Completion Date

2014-12-17

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this multicenter, prospective, randomized clinical study is to determine the safety and effectiveness of the EYEFILL® C.-US Viscoelastic in patients undergoing cataract extraction and intraocular lens (IOL) implantation surgery.

EYEFILL® C.-US Viscoelastic is designed to create and maintain space, to protect the corneal endothelium and other intraocular tissues, and to manipulate tissues during surgery.

EYEFILL® C.-US Viscoelastic may also be used to coat intraocular lenses and instruments during cataract extraction and intraocular lens insertion.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Cataract

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

EYEFILL® C.-US Viscoelastic

EYEFILL ® C.-US is designed for use during cataract extraction and intraocular lens implantation surgery to protect the corneal endothelium, and other intraocular tissues and to manipulate tissues during these anterior chamber ocular surgeries.

Group Type EXPERIMENTAL

EYEFILL® C.-US Viscoelastic

Intervention Type DEVICE

EYEFILL ® C.-US is designed for use during cataract extraction and intraocular lens implantation surgery to protect the corneal endothelium, and other intraocular tissues and to manipulate tissues during these anterior chamber ocular surgeries.

Healon® Viscoelastic (CONTROL)

Healon® is designed for use during cataract extraction and intraocular lens implantation surgery to protect the corneal endothelium, and other intraocular tissues and to manipulate tissues during these anterior chamber ocular surgeries.

Group Type ACTIVE_COMPARATOR

Healon® Viscoelastic (CONTROL)

Intervention Type DEVICE

Healon® is designed for use during cataract extraction and intraocular lens implantation surgery to protect the corneal endothelium, and other intraocular tissues and to manipulate tissues during these anterior chamber ocular surgeries.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

EYEFILL® C.-US Viscoelastic

EYEFILL ® C.-US is designed for use during cataract extraction and intraocular lens implantation surgery to protect the corneal endothelium, and other intraocular tissues and to manipulate tissues during these anterior chamber ocular surgeries.

Intervention Type DEVICE

Healon® Viscoelastic (CONTROL)

Healon® is designed for use during cataract extraction and intraocular lens implantation surgery to protect the corneal endothelium, and other intraocular tissues and to manipulate tissues during these anterior chamber ocular surgeries.

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Any race
* Older than 21 years
* Cataract requiring cataract extraction in at least 1 eye
* Clear intraocular media other than cataract
* Able to provide written informed consent
* Able and willing to comply with required follow-up schedule
* Competent to understand the procedure and the actions asked of him/her as a research subject

Exclusion Criteria

* Monocular
* Ocular infection
* History of glaucoma, Ocular Hypertension (IOP \> 21 mmHg) likely to require IOP lowering medications, ocular condition requiring IOP lowering medication, condition preventing reliable Goldmann applanation tonometry, known steroid responder
* Previous intraocular surgery in the operative eye
* Previous serious corneal disease or known endothelial cell loss / damage (in operative eye)
* History of chronic or recurrent inflammatory eye disease (in operative eye)
* Evidence of retinal vascular disease (in operative eye)
* Uncontrolled diabetes or proliferative diabetic retinopathy
* Acute or chronic disease or illness that would increase the operative risk
* Allergy to anesthetics or other postoperative medications
* Known hypersensitivity to sodium hyaluronate or other components in viscoelastic
* Patient in any other clinical trial within the 30 days prior to the start of the study
Minimum Eligible Age

22 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Bausch & Lomb Incorporated

INDUSTRY

Sponsor Role collaborator

Bausch Health Americas, Inc.

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Donald R Sanders, MD, PhD

Role: STUDY_DIRECTOR

Center for Clinical Research

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Barnet Dulaney Perkins Eye Center

Phoenix, Arizona, United States

Site Status

Shasta Eye Medical Group

Redding, California, United States

Site Status

Argus Research at Cape Coral Eye Center

Cape Coral, Florida, United States

Site Status

Eye Centers of Florida

Fort Myers, Florida, United States

Site Status

Newsom Eye and Laser Center

Sebring, Florida, United States

Site Status

Great Lakes Eye Care

Saint Joseph, Michigan, United States

Site Status

Silverstein Eye Centers

Kansas City, Missouri, United States

Site Status

Comprehensive Eye Care

Washington, Missouri, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

EYE-C-7.00

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.